Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 2.35 420,898 07:36:23
Bid Price Offer Price High Price Low Price Open Price
2.20 2.50 2.35 2.35 2.35
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.84 -0.85 4
Last Trade Time Trade Type Trade Size Trade Price Currency
10:43:56 O 86,650 2.2001 GBX

N4 Pharma (N4P) Latest News

More N4 Pharma News
N4 Pharma Investors    N4 Pharma Takeover Rumours

N4 Pharma (N4P) Discussions and Chat

N4 Pharma Forums and Chat

Date Time Title Posts
28/6/202218:03N4 Pharma3,838
20/5/202108:25N4 Pharma - Making good drugs better.4,391
14/9/202007:40N4P Covid-19 Wealth Warning108

Add a New Thread

N4 Pharma (N4P) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all N4 Pharma trades in real-time

N4 Pharma (N4P) Top Chat Posts

N4 Pharma Daily Update: N4 Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 2.35p.
N4 Pharma Plc has a 4 week average price of 2.30p and a 12 week average price of 2.30p.
The 1 year high share price is 10.25p while the 1 year low share price is currently 2.19p.
There are currently 156,080,349 shares in issue and the average daily traded volume is 108,472 shares. The market capitalisation of N4 Pharma Plc is £3,667,888.20.
ch1rp: ? If you think that then get out the share.
pwal: N4P has got all these patents but when are we going to see sales??
andymunchkin: jayminpatel12 Oct '20 - 13:07 - 2854 of 3787 0 1 3 Pump and dump share ———;— v000w
andymunchkin: Master RSI28 Aug '20 - 11:57 - 2797 of 3785 0 1 0 Able to buy at middle price 11.675p ( 11.50 v 11.75p ) Only WINS at offer 2 at bid Master RSI28 Aug '20 - 12:05 - 2798 of 3785 0 3 0 that's it no more cheap shares, WINS has gone to 12p again 12p 30,000 WINS 13:00 ———;—— Hi MusterBater whats WINS @ now cheers. Btw uSoundLike RampngBufoon whysTht????
earwacks: The rns is obviously unexpected as Nigel admitted the results were 'unexpected.' The point is the trials continue on the vaccine at no cost to N4P. Unfortunately that means no revenue continuing for the time being. However I don't see this as a change in strategy, rather a continuation. The results from Gene therapy have been very encouraging showing not just a suppression in tumours but also a reduction. So why would they not progress this further. Market reaction is understandable. In the longer term I see more positives than negatives. Fortunately this is not a one trick pony
downyr: I'm v cautious as it has shown signs of progress before only to drop back, it needs some v positive news to be able to hold onto any rise. I m not negative but have held this for a while as I believe in what has been said about the potential of their system but have yet to see any real price rise
earwacks: Indeed it it is the future for those that can afford it? I read one of these treatments was going to cost around £500 pounds a course and only a last resort. Not sure the nhs can afford that on mass, although you could argue its cheaper than hospitalisation. Medicines and vaccines are developing rapidly now . Lets hope more rapidly than mutations. I believe N4P are developing oral vaccines. Maybe Novec can also help with delivery of medicines into the body too as with cancer drugs. Preventative medicine is still key
dplewis1: New investors also need to understand that the second largest shareholder in N4 is using multiple aliases to try to ramp the price. David Farrier should fully disclose his position to users on the LSE site that he posts as DanBaker as well as tankerton on here and DaveD on twitter. You don't get a balanced view from share price Angel or someone who holds 7% of a company..
tankerton: The share price Angel analyst report suggested that N4`s share price should be 10 times higher than its current price to align it to its peers. Even at 10 times its current valuation, there would still be a strong argument for a takeover but at its current valuation, it would be a sitting duck to an opportunistic bid. Thankfully I don`t expect N4 to remain at this valuation for much longer as we have a number of big news items coming up.
jakleeds: 09/12/2020 8:10am UK Regulatory (RNS & others) TIDMN4P RNS Number : 0543I N4 Pharma PLC 09 December 2020 9 December 2020 This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 ("MAR"). In addition, market soundings (as defined in MAR) were taken in respect of the Placing with the result that certain persons became aware of inside information (as defined in MAR), as permitted by MAR. This inside information is set out in this announcement. Therefore, those persons that received inside information in a market sounding are no longer in possession of such inside information relating to the Company and its securities. N4 Pharma plc ("N4 Pharma" or the "Company") Placing to raise GBP2 million N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to announce that it has raised GBP2 million (before expenses) through a placing of 25,000,000 new ordinary shares of 0.4p each in the Company (the "Placing Shares") at an issue price of 8p per Placing Share (the "Placing"). The Placing, which was significantly oversubscribed, was undertaken by share price Angel Corporate Finance LLP. The net proceeds of the Placing will be used for: -- the extension of the formulation and current stability work covering DNA and mRNA formulations; -- research on and evaluation of an additional asset to add to the Company portfolio; -- business development driven by study results pending over next six months; and -- ongoing working capital. Nigel Theobald, Chief Executive of N4 Pharma, commented: "We are delighted with the positive response to our recent formulation work. With vaccines and their delivery very much in the public consciousness we continue to grow our data package to present Nuvec(R) as a viable delivery technology solution to improve the delivery, storage and transportation of multiple existing and new vaccines. "Whilst we are well funded for all existing work streams these additional funds will enable us to plan for follow on studies and more product focussed experiments as we move towards collaborations." Application for Admission The Placing has been conducted utilising the Company's existing share authorities. Application has been made for the Placing Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place and that trading will commence on AIM at 8.00 a.m. on or around 14 December 2020. Once issued, the new Ordinary Shares will rank pari passu with the Company's existing ordinary shares. Total Voting Rights Following Admission, the enlarged issued share capital of the Company will comprise 181,080,349 Ordinary Shares of 0.4 pence each. The Company does not hold any ordinary shares in treasury. Consequently, 181,080,349 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
N4 Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
N4 Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220629 13:35:42